Elsevier

Neoplasia

Volume 6, Issue 5, September–October 2004, Pages 623-635
Neoplasia

Genomic Profiles in Stage I Primary Non Small Cell Lung Cancer Using Comparative Genomic Hybridization Analysis of cDNA Microarrays1

https://doi.org/10.1593/neo.04142Get rights and content
Under a Creative Commons license
open access

Abstract

To investigate the genomic aberrations that are involved in lung tumorigenesis and therefore may be developed as biomarkers for lung cancer diagnosis, we characterized the genomic copy number changes associated with individual genes in 14 tumors from patients with primary non small cell lung cancer (NSCLC). Six squamous cell carcinomas (SQCAs) and eight adenocarcinomas (ADCAs) were examined by high-resolution comparative genomic hybridization (CGH) analysis of cDNA microarray. The SQCAs and ADCAs shared common frequency distributions of recurrent genomic gains of 63 genes and losses of 72 genes. Cluster analysis using 57 genes defined the genomic differences between these two major histologic types of NSCLC. Genomic aberrations from a set of 18 genes showed distinct difference of primary ADCAs from their paired normal lung tissues. The genomic copy number of four genes was validated by fluorescence in situ hybridization of 32 primary NSCLC tumors, including those used for cDNA microarray CGH analysis; a strong correlation with cDNA microarray CGH data emerged. The identified genomic aberrations may be involved in the initiation and progression of lung tumorigenesis and, most importantly, may be developed as new biomarkers for the early detection and classification of lung cancer.

Keywords

Genomic copy number changes
primary non small cell lung cancer
comparative genomic hybridization
cDNA microarray

Cited by (0)

1

This work was supported by an M. Keck Center for Cancer Gene Therapy Award, the University of Texas M. D. Anderson Cancer Center Institutional Research Grant, the Developmental Project/Career Development Award from The University of Texas specialized programs of research excellence in lung cancer, and the M. D. Anderson Cancer Center Tobacco Settlement Fund.